转录因子Helios抑制CD8+ T细胞的抗瘤能力
Rosa M Rubio1, Gerardo Suárez-Rojas2, Adrián Albarrán-Godínez2
1Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
Cell reports
|December 12, 2025
概括
转录因子Helios限制了癌症中抗瘤CD8+T细胞的反应. 抑制Helios通过恢复T细胞功能和减少瘤生长来提高免疫疗法的有效性.
科学领域:
- 免疫学 免疫学 免疫学
- 癌症生物学 癌症生物学
- 分子生物学分子生物学
背景情况:
- 免疫疗法已经改变了癌症治疗,但对于许多患者来说,它的有效性受到限制.
- 了解影响CD8+T细胞抗瘤活性的分子机制对于改善治疗结果至关重要.
研究的目的:
- 研究转录因子Helios在调节癌症期间CD8+T细胞耗尽中的作用.
- 探索Helios作为增强抗癌免疫疗法的潜在治疗点.
主要方法:
- 从人类和小鼠癌症模型中分析瘤透的CD8+T细胞中Helios表达的分析.
- 在CD8+T细胞中基因删除Helios,以评估其对瘤生长和T细胞功能的影响.
- 染色体可访问性测试用于研究基因调节.
- 评估涉及Helios抑制和PD-1阻塞的组合疗法.
主要成果:
- 在人类和小鼠癌症中,Helios在瘤透的CD8+T细胞中被上调.
- 对Helios的遗传删除减少了瘤生长,并减少了终极耗尽的CD8+ T细胞.
- 失去Helios会增加具有原始细胞潜力的CD8+ T细胞,并增强与干性相关的基因可访问性.
- 联合缺乏Helios和PD-1显著改善了抗瘤CD8+T细胞的反应.
- 一种新型的Helios抑制剂在临床前模型中增强了PD-1阻断的有效性.
结论:
- 体是瘤微环境中CD8+T细胞耗尽的关键调节者.
- 准Helios是一种有前途的策略,可以克服免疫疗法耐药性并增强抗癌T细胞活性.
- 体抑制可以与PD-1阻断等现有免疫疗法协同作用.
关键词:
BNTX BNTX BNTX BNTX BNTX BNTX BNTX BNTX BNTX BNTX BNTX BNTX BNTXCD8 (((+) T细胞是T细胞中的一个.CP:癌症的癌症.CP: 免疫学 免疫学希利奥斯 (Helios) 是一个星球.在 IKZF2在PD-1中使用PD-1.T细胞耗尽的情况这就是TILs.免疫疗法 免疫疗法瘤免疫力 免疫力瘤透的T细胞更多相关视频
08:06Determination of Regulatory T Cell Subsets in Murine Thymus, Pancreatic Draining Lymph Node and Spleen Using Flow Cytometry
Published on: February 27, 2019
12.1K
10:13Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
Published on: May 6, 2019
9.4K
相关概念视频
Regulation of Hematopoietic Stem Cells
3.9K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.9K
Replicative Cell Senescence
4.3K
Replicative cell senescence is a property of cells that allows them to divide a finite number of times throughout the organism's lifespan while preventing excessive proliferation. Replicative senescence is associated with the gradual loss of the telomere — short, repetitive DNA sequences found at the end of the chromosomes. Telomeres are bound by a group of proteins to form a protective cap on the ends of chromosomes. Embryonic stem cells express telomerase — an enzyme that adds...
4.3K
Abnormal Proliferation
5.1K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.1K
T Cell Types and Functions
2.1K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
2.1K
T Cell Activation and Clonal Selection
14.6K
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
14.6K
Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
